Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Guardant Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Guardant Health's regulatory disclosures and financial reporting.
Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity. On June 15, 2026, 2,039 Restricted Stock Units were converted into an equal number of shares of common stock, reflecting the vesting schedule of an award granted on June 9, 2023.
On the same date, 1,096 shares of common stock were withheld by the company to cover Mr. Bell’s tax withholding obligations tied to this vesting, with the shares valued at $129.82 each. After these transactions, Mr. Bell directly owned 48,452 shares of Guardant Health common stock.
Guardant Health (GH) notice of proposed insider sales by Musa Tariq. The filing lists prior sales of common stock in three separate transactions: 03/18/2026 — 348 shares (aggregate $30,655), 04/16/2026 — 116 shares (aggregate $9,840), and 05/18/2026 — 116 shares (aggregate $11,131).
The filing also records a restricted stock lapse on 06/15/2026 associated with equity compensation and lists brokerage details for Charles Schwab & Co. The notice records proposed sale activity under Form 144; timing and method of any future sales are not detailed beyond the listed items.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 3,418 shares of Common Stock on June 11, 2026 at an average price of $130.2386 per share. After this transaction, Kalia directly holds 41,090 shares, indicating he retains a substantial ongoing equity stake.
GH affiliate reported a proposed sale of 5,000 shares of Common Stock by Kumud Kalia on 06/10/2026, with a reported gross value of $652,030.00. The filing lists prior open-market purchases of 2,231 shares on 06/09/2023 and 2,187 shares on 03/18/2024.
GH affiliate filing amends a prior Form 144. The filing reports a sale of 5,000 shares on 06/10/2026 for $652,030 and lists 600 shares purchased on 06/09/2023 via open-market purchase. The broker on record is Fidelity Brokerage Services LLC.
Form 144 notice of proposed sales by Kumud Kalia and a prior purchase record. The filing lists sales by Kumud Kalia of 6,839 shares on 03/15/2026 for $584,666.00, 5,092 shares on 04/01/2026 for $464,135.80, and 5,000 shares on 06/10/2026 for $652,030.00. The record also shows Fidelity Brokerage Services LLC purchased 600 shares in an open-market purchase on 06/09/2023.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 5,000 shares of Common Stock. The shares were sold at a price of $130.406 per share. After this transaction, Kalia directly owns 44,508 shares, indicating a remaining substantial equity position.
Guardant Health, Inc. Co-Chief Executive Officer Helmy Eltoukhy reported a series of open-market sales of the company’s common stock on June 5, 2026. Through the Helmy A. Eltoukhy Revocable Trust, he sold a total of 100,000 shares in seven transactions at weighted average prices between about $124.95 and $132.55 per share. Following these sales, the trust continues to hold approximately 2,012,919 shares of Guardant Health common stock indirectly attributed to Eltoukhy.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell sold 2,000 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $128.6203 per share. Following this sale, he directly holds 47,509 shares of Guardant Health common stock.
The footnote explains that the sale occurred through multiple trades at prices ranging from $128.620 to $128.955 per share, and detailed trade-level information is available upon request.